Literature DB >> 19276271

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.

Margaret A Leversha1, Jialian Han, Zahra Asgari, Daniel C Danila, Oscar Lin, Rita Gonzalez-Espinoza, Aseem Anand, Hans Lilja, Glenn Heller, Martin Fleisher, Howard I Scher.   

Abstract

PURPOSE: To assess the feasibility of characterizing gene copy number alteration by fluorescence in situ hybridization (FISH) of circulating tumor cells (CTC) isolated using the CellSearch system in patients with progressive castration-resistant metastatic prostate cancer. EXPERIMENTAL
DESIGN: We used probe combinations that included the androgen receptor (AR) and MYC genes for FISH analysis of CTC samples collected from 77 men with castration-resistant metastatic prostate cancer.
RESULTS: High-level chromosomal amplification of AR was detected in 38% and relative gain of MYC in 56% of samples analyzed. No such abnormalities were detected in samples with CTC counts of <10, reflecting ascertainment difficulty in these lower count samples.
CONCLUSION: The CTC isolated from our patient cohort present a very similar molecular cytogenetic profile to that reported for late-stage tumors and show that FISH analysis of CTC can be a valuable, noninvasive surrogate for routine tumor profiling. That as many as 50% of these patients have substantial amplification of the AR locus indicates that androgen signaling continues to play an important role in late-stage prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276271      PMCID: PMC2875199          DOI: 10.1158/1078-0432.CCR-08-2036

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones.

Authors:  Heike Fiegler; Philippa Carr; Eleanor J Douglas; Deborah C Burford; Sarah Hunt; Carol E Scott; James Smith; David Vetrie; Patricia Gorman; Ian P M Tomlinson; Nigel P Carter
Journal:  Genes Chromosomes Cancer       Date:  2003-04       Impact factor: 5.006

2.  Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer.

Authors:  Norihiko Tsuchiya; Yasushi Kondo; Atsushi Takahashi; Hemant Pawar; Junqi Qian; Kazunari Sato; Michael M Lieber; Robert B Jenkins
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

3.  Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Authors:  W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

4.  Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.

Authors:  R S D Brown; J Edwards; A Dogan; H Payne; S J Harland; J M S Bartlett; J R W Masters
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

5.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

6.  Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

Authors:  Tanja Fehm; Arthur Sagalowsky; Edward Clifford; Peter Beitsch; Hossein Saboorian; David Euhus; Songdong Meng; Larry Morrison; Thomas Tucker; Nancy Lane; B Michael Ghadimi; Kerstin Heselmeyer-Haddad; Thomas Ried; Chandra Rao; Jonathan Uhr
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

Review 7.  Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.

Authors:  Howard I Scher; Grant Buchanan; William Gerald; Lisa M Butler; Wayne D Tilley
Journal:  Endocr Relat Cancer       Date:  2004-09       Impact factor: 5.678

8.  Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors.

Authors:  Herman van Dekken; Janneke C Alers; Irma A A J Damen; Kees J Vissers; Pieter-Jaap Krijtenburg; Robert F Hoedemaeker; Mark F Wildhagen; Wim C J Hop; Theodorus H van der Kwast; Hans J Tanke; Fritz H Schröder
Journal:  Lab Invest       Date:  2003-06       Impact factor: 5.662

9.  Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics.

Authors:  H Engel; C Kleespies; J Friedrich; M Breidenbach; A Kallenborn; T Schöndorf; H Kolhagen; P Mallmann
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  81 in total

Review 1.  Challenges in circulating tumour cell research.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2014-07-31       Impact factor: 60.716

Review 2.  Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Authors:  Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina
Journal:  Endocr Relat Cancer       Date:  2015-02-26       Impact factor: 5.678

3.  Circulating tumor cells: finding the needle in the haystack.

Authors:  Xiaoning Zhe; Michael L Cher; R Daniel Bonfil
Journal:  Am J Cancer Res       Date:  2011-06-01       Impact factor: 6.166

4.  A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.

Authors:  Ronald Rodriguez; Shawn E Lupold; Ping Wu; Lori J Sokoll; Tarana A Kudrolli; Wasim H Chowdhury; Rong Ma; Minzhi M Liu
Journal:  Prostate       Date:  2014-07-25       Impact factor: 4.104

Review 5.  New hormonal therapies for castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel; Stephen Plymate
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-14       Impact factor: 4.741

6.  Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems.

Authors:  Sangjo Shim; Katherine Stemke-Hale; Jamileh Noshari; Frederick F Becker; Peter R C Gascoyne
Journal:  Biomicrofluidics       Date:  2013-01-16       Impact factor: 2.800

Review 7.  Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Authors:  Daniel P Petrylak; E David Crawford
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

8.  Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.

Authors:  Giuseppe Galletti; Luigi Portella; Scott T Tagawa; Brian J Kirby; Paraskevi Giannakakou; David M Nanus
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

Review 9.  Dormancy in solid tumors: implications for prostate cancer.

Authors:  Nazanin S Ruppender; Colm Morrissey; Paul H Lange; Robert L Vessella
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

10.  Circulating tumor cell analysis: technical and statistical considerations for application to the clinic.

Authors:  Alison L Allan; Michael Keeney
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.